Colorectal Cancer Clinical Trial
Official title:
Electroacupuncture Promotes Gastrointestinal Functional Recovery After Radical Colorectal Cancer Surgery: a Multicenter Randomized Controlled Study
The goal of this clinical trial is to verify the efficacy of electroacupuncture in accelerating the recovery of gastrointestinal function after colorectal cancer surgery. The main questions it aims to answer are: - Whether electroacupuncture can accelerate the recovery of gastrointestinal function in patients after colorectal cancer surgery. - Whether electroacupuncture intervention is safe for postoperative colorectal cancer patients. Participants will be randomized into 3 groups: The conventional control group will receive postoperative rehydration and nutritional support, correction of acid-base imbalance and electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatments. In the electroacupuncture group, acupuncture will be performed within 6 hours after surgery on the basis of the conventional control group. Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). Both after obtaining Qi, and unilaterally connected to the electroacupuncture instrument for electrical stimulation, the current frequency is continuous wave 5 Hz, the intensity of stimulation was as the patient tolerated, each time lasting 30 min. Acupuncture stimulation was given every 12 h. The course of treatment was terminated postoperatively until the fourth postoperative day (d0-d4) or until the patient showed the first postoperative anal exhaust or continued until the fourth day. The sham acupuncture group will based on the conventional control group, using a blunt-tipped needle tip that do not pierce the adhesive pad.
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | January 30, 2025 |
Est. primary completion date | January 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility | Inclusion Criteria: 1. Surgical patients who meet the diagnostic criteria for colorectal cancer and require elective radical colorectal cancer surgery; 2. 18 years old = age = 79 years old, with no restriction on gender; 3. Understand, agree to participate in this study and sign the informed consent form; 4. American society of Aneshesiologists (ASA) classification I to III. Exclusion Criteria: 1. Patients with psychiatric disorders; 2. Patients who have participated or are participating in other clinical studies in the 3 months prior to enrollment; 3. Patients with severe malnutrition (NRS2002 score = 3); 4. Patients with total colectomy; 5. Patients undergoing ileal diversion for rectal cancer; 6. Patients with tumor infiltration requiring resection of other organs; 7. Prophylactic fistulae. Anyone who meets any of the above criteria will be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Yueyang Integrated Medicine Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Yueyang Integrated Medicine Hospital | Shanghai Baoshan hospital of Integrated Traditional Chinese and Western Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, ShuGuang Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse Event Assessment | Any adverse events in the study. | up to 4 days | |
Primary | Time of first postoperative exhaust | The time between the patient's first exhaust and the end of surgery will be recorded. | up to 4 days after surgery. | |
Secondary | Time of first postoperative defecation | Patients self-report their defecation and doctors record the time. | up to 4 days after surgery. | |
Secondary | Length of recovery of bowel sounds after surgery ( Yueyang Hospital records only) | Monitoring by continuous auscultation recorder of bowel sounds immediately at the end of surgery; Determination of recovery of postoperative bowel sounds: the time point when regular bowel sounds are observed and greater than 4 times/minute, calculate its time until the end of surgery (h), this outcome is only used in our center. | up to 4 days after surgery. | |
Secondary | Time of first postoperative intake of water | The time when the patient first entered water after surgery was recorded separately. | up to 4 days after surgery. | |
Secondary | Number of Postoperative nausea and vomiting episods | During the postoperative hospitalization, whenever nausea, vomiting and abdominal distension occur, patients or their family members use the uniform tabulation to record the occurrence time by themselves and inform the medical staff in time, and the medical staff keep records at the same time. The time until the end of the operation and the number of postoperative episodes will be calculated before discharge. | up to 4 days after surgery. | |
Secondary | Quality of life scale 1 | Version 3.0 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), standard score, range from 0 to 100, higher scores mean a better outcome. | baseline, discharge 1 day, 1 month after surgery. | |
Secondary | Quality of life scale 2 | Short Form 12 scale (Chinese version). (Short Form 12 scale consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability). | baseline, discharge 1 day, 1 month after surgery. | |
Secondary | Visual Analog Scale (VAS) of Pain | Visual analogy score (0 to 5, higher scores mean a worse outcome) | up to 4 days after surgery. | |
Secondary | Postoperative hospitalization days | Calculate and record the number of days from the day of surgery to the day of patient discharge. | up to 4 days | |
Secondary | Biochemical indexes 1 | Hypersensitive C-reactiveprotein (hs-CRP), µg/L. | 1 hour postoperatively, 12 hours postoperatively, 72 hours postoperatively. | |
Secondary | Biochemical indexes 2 | Interleukin-6 (IL-6), µg/L. | 1 hour postoperatively, 12 hours postoperatively, 72 hours postoperatively. | |
Secondary | Biochemical indexes 3 | serum albumin (ALB), g/L. | baseline, discharge 1 day. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |